Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(22):1643; doi:10.1093/jnci/96.22.1643
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2004 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

BRCA1 and the Cellular Response to Chemotherapy

Germline mutations in the BRCA1 gene account for approximately 5% of breast and ovarian cancers, and lower than normal BRCA1 expression may be an important factor contributing to sporadic cancers. BRCA1 responds to damaged DNA by participating in DNA repair pathways, mRNA transcription, cell cycle regulation, and protein ubiquitination. Because most chemotherapeutic agents either directly or indirectly damage DNA, the association between BRCA1 activity and chemotherapy-induced DNA damage has been investigated. Kennedy et al. (p. 1659) review the evidence that the level of BRCA1 function in an individual patient can guide the . . . [Full Text of this Article]

Selenium and Colorectal Cancer

Neoadjuvant Chemotherapy in Head and Neck Cancer

Docetaxel and Carboplatin in Ovarian Cancer

Pneumonitis After Paclitaxel and Radiation for Breast Cancer

Methotrexate and EBV-Positive Lymphomas